Journal: Molecular Vision

Article Title: Ex vivo expanded SSEA-4+ human limbal stromal cells are multipotent and do not express other embryonic stem cell markers

doi:

Figure Lengend Snippet: Expression profiles of limbal stromal (LS) at passage 6 and corneal stromal (CS) cells at passage 4 by FACS analysis. The two populations of cells have very similar expression where they expressed mesenchymal markers and absence of hematopoietic markers and endothelial marker (CD31). The cells did not express ABCG2 and other embryonic stem cells markers. The green line in the histograms represents the isotype controls.

Article Snippet: Embryonic stem cell line, BG01V (ATCC) at passage 16 were cultured on mitomycin treated MEF cells (ATCC) with 80% knockout DMEM supplemented with 20% Gibco knockout SR, 1% MEM-non essential amino acid (NEAA), 1% Glutamax, 0.1 mM B-mercaptoethanol (BME), 10 IU/ml penicillin, 10 μg/ml streptomycin (all from Invitrogen Corporation), and 4 ng/ml human basic fibroblast growth factor (bFGF; BD Biosciences) [ ].

Techniques: Expressing, Marker

Journal: PLoS ONE

Article Title: Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible?

doi: 10.1371/journal.pone.0042289

Figure Lengend Snippet: ( A ) Bar graph showing GM-CSF expression in non-transduced and retrovirally transduced STO fibroblasts. Error bars represent mean ± SD. *, p<0.05; relative to non-transduced STO cells; t test. ( B ) Scheme of immunization. Male C57BL/6 mice were immunized twice (days 0 and 14) with HBSS (control), or irradiated 1×10 6 ESC+irradiated 1×10 6 GM-CSF-expressing STO murine embryonic fibroblasts (STO-GM) s.c. in the right flank. Seven days after boost, mice were challenged with 1×10 5 Lewis lung carcinoma cells (LLC) s.c. in the left flank. ( C ) C57BL/6 mice (10/group) were immunized twice (days 0 and 14) with HBSS (control), or irradiated 1×10 6 ESC+irradiated 1×10 6 STO-GM, or irradiated 1×10 6 STO-GM cells alone s.c. in the right flank prior to s.c. challenge with LLC on day 21. Tumor growth was monitored daily in all animals until sacrifice due to tumors exceeding 5% of body weight. The vaccinated tumor free mice remained so for up to 4 months later with no overt signs of distress or autoimmunity. are representative of three independent experiments. **, p <0.001; relative to control group; log-rank test. ( D ). Tumor growth was measured by calipers every 2nd or 3rd day and tumor volumes were plotted as indicated. The data represent the average tumor volumes of 10 mice/control group and 3 mice/ESC/STO-GM group and are representative of three independent experiments. Error bars represent mean ± SEM.

Article Snippet: As a vaccine, we employed the murine embryonic stem cell (ESC) line, ES-D3 (ATCC CRL-11632), derived from 129/Sv mice (expressing MHC class II I-E).

Techniques: Expressing, Control, Irradiation

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Transplantation of tissues and cells to provide novel neuronal connections & an anatomical relay for spinal cord repair.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Transplantation Assay, Suspension, Cell Culture

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Transplantation of tissues and cells to provide neuroprotection of spinal cord tissue.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Transplantation Assay, Derivative Assay, Cell Culture

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Clinical trials transplanting tissue and cells for spinal cord repair.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Clinical Proteomics, Modification, Derivative Assay, Transplantation Assay, Functional Assay, Control, Cell Culture

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Schematic diagram highlighting potential sources of neural stem and precursor cells: the developing neural tissues (A), pluripotent embryonic stem cells (B), and induced pluripotent stem cells (C; exemplified by skin fibroblast de-differentiation/reprogramming). These cells can be engineered to produce neural stem and progenitor cells that can then be expanded (D), specific subsets selected (e.g., NRPs and GRPs), and cryopreserved for “cell banking.” These cell stores can be thawed and prepared for transplantation into the injured spinal cord (E) alone, or in combination with additional treatments (E), including rehabilitation and activity-based therapy, neural interfacing and neuromodulation, application of scaffolds/biomaterials, or additional pharmaceuticals to enhance efficacy. Figure modified from Zholudeva, L. V., & Lane, M. A. (2022). Spinal interneurons: Plasticity after spinal cord injury, 1st ed. Academic Press.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Transplantation Assay, Activity Assay, Modification